Shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) have been assigned an average recommendation of “Buy” from the six research firms that are currently covering the stock, AnalystRatings.Net reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $20.33.
Shares of Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 7.19 on Monday. The stock has a 50 day moving average of $7.80 and a 200 day moving average of $11.95. The stock’s market cap is $157.25 million. Vitae Pharmaceuticals has a 1-year low of $4.08 and a 1-year high of $18.71.
Vitae Pharmaceuticals (NASDAQ:VTAE) last announced its quarterly earnings data on Thursday, March 3rd. The company reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.10. The firm had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.14 million. During the same quarter in the previous year, the company posted ($0.40) EPS. The firm’s quarterly revenue was down 42.9% compared to the same quarter last year. Equities research analysts forecast that Vitae Pharmaceuticals will post ($2.24) EPS for the current year.
In other Vitae Pharmaceuticals news, Director Donald J. Hayden, Jr. sold 16,130 shares of the company’s stock in a transaction on Tuesday, December 29th. The stock was sold at an average price of $18.00, for a total value of $290,340.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey S. Hatfield sold 22,524 shares of the company’s stock in a transaction on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total value of $382,908.00. Following the completion of the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The disclosure for this sale can be found here.
An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Candriam Luxembourg S.C.A. purchased a new position in shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 133,000 shares of the company’s stock, valued at approximately $2,407,000. Candriam Luxembourg S.C.A. owned approximately 0.61% of Vitae Pharmaceuticals as of its most recent filing with the SEC.
VTAE has been the subject of several analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $22.00 price target on shares of Vitae Pharmaceuticals in a report on Wednesday, December 30th. Wedbush reissued an “outperform” rating and set a $20.00 target price on shares of Vitae Pharmaceuticals in a research note on Monday, January 4th. Piper Jaffray reissued a “buy” rating and issued a $23.00 price target (up from $18.00) on shares of Vitae Pharmaceuticals in a report on Monday, January 4th. Wells Fargo initiated coverage on Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research raised Vitae Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 5th.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
